Since PAS starting dose exerted a beneficial impact on IGF-I levels in the long term without a dose-related hyperglycemic effect, choosing to start PAS therapy with a high dose could be an useful and safe approach to improve biochemical control in acromegaly patients with resistance to first-generation SRLs. The gene discussed is IGF1; the disease is acromegaly.